基于Illumina单轮扩增NGS可早期可靠检测CML的BCR-ABL1激酶域突变
本研究针对慢性髓性白血病(CML)患者BCR-ABL1激酶域(KD)突变检测,开发了一种简化的单轮扩增Illumina平台NGS方案。该方案可实现BCR-ABL1 KD突变的稳健早期检测,可靠检测限为3%变异等位基因频率(VAF)。
要点
- 单轮扩增NGS方案可早期检测BCR-ABL1 KD突变。
- 该方案可靠检测限为3%变异等位基因频率。
- 相比多轮扩增方案,简化了流程并提高检测灵敏度。
核心结论
- 单轮扩增Illumina NGS方案可实现BCR-ABL1 KD突变的稳健早期检测,可靠检测限为3% VAF。
研究设计与样本
- 本研究开发并验证了一种简化的单轮扩增NGS方案,基于Illumina平台检测BCR-ABL1 KD突变。
主要发现
- 该单轮扩增NGS方案的可靠检测限为3%变异等位基因频率。
关键数值与推荐
- 可靠检测限为3%变异等位基因频率。
临床怎么用
- 可用于CML患者BCR-ABL1 KD突变的早期可靠检测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The occurrence of mutations in the BCR-ABL1 kinase domain (KD) can lead to treatment resistance in chronic myeloid leukaemia patients. Nowadays, next-generation sequencing (NGS) is an alternative method for the detection of kinase domain mutations, compared to routinely used Sanger sequencing, providing a higher sensitivity of mutation detection. However, in the protocols established so far multiple rounds of amplification limit reliable mutation detection to approximately 5% variant allele frequency. Here, we present a simplified, one-round amplification NGS protocol for the Illumina platform, which offers a robust early detection of BCR-ABL1 KD mutations with a reliable detection limit of 3% variant allele frequency.
引用
- Romzova M, Smitalova D, Tom N, et al. Novel Illumina-based next generation sequencing approach with one-round amplification provides early and reliable detection of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia. Br J Haematol. 2020. PMID: 32037516. doi:10.1111/bjh.16382
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。